medigraphic.com
ISSN 0028-3851 (Print)

2005, Number 4

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2005; 38 (4)

Cerebrovascular disease in the Military Central Hospital: a descriptive study

Aguilar GOR, Alegría LMA, Salazar ZA

Language: Spanish
References: 20
Page: 135-139
PDF size: 61.42 Kb.


ABSTRACT

Background. Cerebrovascular disease is the third cause of death in the world and the incidence is about 730,000 cases per year in the U.S.
Objective. To describe a case series of stroke over a year at the Military Central Hospital (MCH).
Method. A descriptive-retrospective study was done through chart review of stroke patients Jan to December, 2002.
Results. A total of 163 patients were admitted with stroke to the Central Military Hospital, 84 (52%) were women and 79 (48%) were men. The distribution by types of stroke was: cerebral infarction 65%, cerebral hemorrhage and trascient ischemic atack 15% each, and subarachnoid hemorrhage 5%. The more affected hemisfere was the left (60%) in the cerebral infarction patients and the anterior circulation was the most affected (95%).
Conclusions. These features are similar to those reported in world literature. It is important to continue this line of research in order to confirm the consistency of these results.


REFERENCES

  1. Adams R. Enfermedades vasculares cerebrales. México: Principios de Neurología; 1995, p. 675-757.

  2. Ames A, Nesbett FB. Pathophysiology of ischemic cell death: 1. Time of onset of irreversible damage; importance of the different components of the ischemic insult. Stroke 1993; 14: 219.

  3. Ames A, Nesbett FB. Pathophysiology of ischemic cell death. II. Changes in plasma membrane permeability and cell volume. Stroke 1993; 14: 227.

  4. Ames A, Nesbett FB. Pathophysiology of ischemic cell death: III. Role of extracellular factor. Stroke 1983; 14: 233.

  5. The NINDS t-PA Stroke Study Group. Generalized Efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA stroke trial stroke, 1997; 128: 2119-25.

  6. Report of the Quality standards Subcommittee of the American Academy of Neurology. Practice Advisory: thrombolytic therapy for acute ischemic stroke summary statement. Neurology 1996; 47: 835-9.

  7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.

  8. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997; 28: 2119-25.

  9. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke a supplement to the guidelines for the management of patients with acute-ischemic stroke. A statement for healthcare professionals from a Special Writing group of the Stroke Council, American Heart Association. Stroke 1996; 27: 1711-8.

  10. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice Advisory – thrombolytic therapy for acute ischemic stroke-summary statement. Neurology 1996; 47: 835-9.

  11. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-18.

  12. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20 (7): 864-70.

  13. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: Extension to non-neurologists in the context of a clinical trial. Stroke 1997; 28: 307-10.

  14. A Statement for Health Professionals. Cardiovascular diseases and stroke in African-Americans and others racial minorities in the United States. Stroke 1991; 22: 552-69.

  15. WHO-MONICA. Proyect Principal Investigators (prepared by J. Tunstall Pedoe). J Clin Epidemiol 1998; 41: 105-14.

  16. Barnett HJM. 35 Years of Stroke Prevention: Challenges, disa-pointments and successes. Cerebrovasc Dis 1991; 1: 61-70.

  17. Barnett HJM, Stein BM, Mohr JP, Yatsu FM. Stroke: pathophys-iology, diagnosis and management. New York: Churchill Linvingstone; 1993.

  18. Barinagarrementería F, Cantú C, Arauz A. Terapéutica de la EVC. México, Grupo Ixel 2001; 1: 7-8.

  19. Harris CL, Ferrel RE, Barton SA, Aguilar R, Garza-Ibarra A, Tul-loch BR, García CA, Schull WJ. Diabetes among Mexican-Americans in Star Country, Texas. Am J Epidemiol 1983; 118: 659-72.

  20. Arauz A. Registro de EVC en el I.N.N. y N. Tesis. México, 1995.




2020     |     www.medigraphic.com